Assessing Ocular Surface Changes After Changing Glaucoma Medications

Completed

Conditions studied: Glaucoma, Monotherapy With Xalatan From 1 to 18 Months, Ocular Surface Disease

In brief

Hypothesis: Changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.

Key facts

Study ID

NCT00554411

Run by

University of Colorado, Denver

People needed

22

Starts

2007-11-01

Expected to finish

2011-08-01

Last updated by the study team

2017-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• on Xalatan monotherapy from 1 to 18 months
• 18 years of age or older
• has been diagnosed with ocular surface disease

You may not qualify if…

• special populations such as children, pregnant females, prisoners, etc.

Where it is running

• Rocky Mountain Lions Eye Institute — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.